According to the sci tech Innovation Board daily, the preprint platform of the medical academic journal the lancet has published the main results of the phase II clinical study of Fosun medicine mRNA new crown vaccine "fubitai" in China a few days ago: among Chinese adults who are healthy or suffering from stable basic diseases, two doses of fubitai every 21 days can induce strong immune response and have good safety.
Access:
It is reported that this is the first new mRNA crown vaccine to disclose phase II clinical data of Chinese population.
The vaccine was developed by German biontech. In March, 2020, Fosun Pharmaceutical was authorized to develop and commercialize exclusively in Chinese Mainland, Hong Kong, Macao and Taiwan.
